Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b (ADHERENCE)

Bayer

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

Study type: Observational

Funder types: Industry

Identifiers

NCT03408093

2008/01880

Details and patient eligibility

About

The primary objective of the study is to evaluate the adherence to the treatment with interferon beta-1b, in patients diagnosed with isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), or secondary progressive multiple sclerosis (SPMS) who had more than 6 months in treatment.

Enrollment: 120 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) or patients with a first outbreak or clinically isolated syndrome (CIS) that carry more than 6 months in treatment with interferon beta-1b

Exclusion criteria

Trial design

120 participants in 1 patient group

Interferon beta-1b

Description:

Patients with CIS, RRMS or SPMS who had more than 6 months in treatment

Treatment:

Drug: Interferon beta-1b (Betaseron, BAY86-5046)